Business Wire

Labcyte and FIMM Extend Personalized Medicine Collaboration

Jaa

Labcyte Inc. and the Institute for Molecular Medicine Finland (FIMM), a unit of the Helsinki Institute of Life Science at the University of Helsinki today announced they are extending their personalized medicine collaboration to include multiple new applications that leverage the unique capabilities of Labcyte’s Echo® liquid handler and Access™ automation platform. The organizations first began collaborating in 2013 to develop new personalized medicine strategies to treat cancer based on functional cell screening.

At FIMM, scientists have developed an innovative approach to cancer care that first involves testing the effects of hundreds of different drug options on the patient’s cancer cells in the lab, a process that is uniquely enabled by Labcyte’s acoustic liquid handling technology. Combined with the patient’s DNA data, this information can help doctors create a tailored treatment plan in real time.

The collaboration has been expanded to include cell-based assay development and screening, such as lysate-based assays for multiplexing and standard miniaturized assays; the development of advanced cell models, such as spheroid/organoid assays, cellulose matrix for 3D cell culture, and flow cytometry assays; and integration of the Echo liquid handler in FIMM’s genomics program to include single cell genomics and population genetics workflows.

“The collaboration with FIMM has been one of our most successful and productive to date,” said Mark Fischer-Colbrie, Chief Executive Officer at Labcyte. “We have been working together for the past four years to break new ground in personalized medicine and functional cell screening, and this work is being modeled now in many centers around the world. The team at FIMM have enabled patients to achieve remission and identified drugs and drug combinations that can be used more broadly. We are looking forward to working on these new projects.”

“FIMM’s Individualized Systems Medicine in Cancer program has greatly benefited from Labcyte’s acoustic liquid handling technology,” said Janna Saarela, Research Director at FIMM and the Head of the FIMM Technology Centre. “Our collaboration has been essential for the successful drug sensitivity testing assays we have set up. Now we aim to expand the use of Labcyte’s equipment to our genomic workflows, enabling us to miniaturize assays, make complex liquid handling processes simple, and explore the use of acoustic liquid handling for biobanked DNA samples.”

For more information, please visit http://www.labcyte.com/applications/personalized-medicine

About Labcyte Inc.

Labcyte, a global biotechnology tools company headquartered in San Jose, California, is revolutionizing liquid handling. Echo® liquid handling systems uses sound to precisely transfer liquids without contact, eliminating the use of pipettes. Labcyte instruments are used worldwide throughout the pharmaceutical and biotechnology industries, as well as by hospitals, service laboratories, contract research organizations, and academic institutions. Our customers work across a wide spectrum of scientific research, including drug discovery, genomics, proteomics, diagnostics and personalized medicine. Labcyte has 61 U.S. patents and others internationally. For more information, visit www.labcyte.com.

About FIMM

Institute for Molecular Medicine Finland (FIMM) is an international research institute in Helsinki focusing on human genomics and personalized medicine. In the beginning of 2017 FIMM joined the University of Helsinki’s new life science research center, Helsinki Institute of Life Science HiLIFE, as an operational unit. FIMM integrates molecular medicine research, technology center and biobanking infrastructures under one roof, promoting translational research in grand challenge projects, specifically, the impact of genome information from the Finnish population in personalized health and medicine, individualized cancer medicine, and digital diagnostics for precision medicine. FIMM is part of the Nordic EMBL Partnership in Molecular Medicine and the EU-LIFE alliance. For more information, visit www.fimm.fi/en/.

Contact information

Bioscribe, Inc. for Labcyte
Nicole Litchfield, 415-793-6468
nicole@bioscribe.com
or
Institute for Molecular Medicine Finland (FIMM)
HiLIFE, University of Helsinki
Mari Kaunisto
mari.kaunisto@helsinki.fi

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Madison Realty Capital Provides $64.0 Million Construction Financing for 200 Kent Avenue Development in Williamsburg, Brooklyn17.11.2017 19:20Tiedote

Madison Realty Capital (MRC) announced the closing of a $64.0 million construction loan for 200 Kent Avenue, a 117,326 square foot mixed-use development located in Williamsburg, Brooklyn. The retail portion of the property, which will include over 600 feet of frontage, will be anchored by a popular national grocery chain. Overall, the project will offer 50,101 square feet of retail space, 22,055 square feet of office and restaurant space, and 45,170 square feet of parking. “We continue to establish MRC as the one-stop shop for financing transitional real estate, including ground-up development deals like 200 Kent Avenue,” said Josh Zegen, Co-Founder and Managing Principal of MRC. “In this case, we’re working with a repeat MRC borrower who understands our ability to execute efficiently, given our firm’s up-to-the minute knowledge of local market conditions and non-bureaucratic approach to

Ncardia Announces Completion of €10.5M Investment Round17.11.2017 15:31Tiedote

Ncardia, an emerging drug discovery and development stem cell technology company whose mission is to deliver cardiac and neural solutions based on its best-in-class human induced pluripotent stem cell (iPSC)-derived technology, today announced the completion of a €10.5 million series B financing round. The round was led by Épimède, a Belgium venture capital firm. Ncardia is a privately-held company with operations in Europe and the US, that produces and commercializes high-quality, fully-functional human iPSC-derived cardiovascular and neuronal cell types. Using its cell products, Ncardia develops and commercializes assay services for drug safety and efficacy testing. Additionally the company has built up a strong portfolio of patents covering the use of stem cell models for these applications. Stefan Braam, CEO of Ncardia, commented: “At Ncardia, important progress h

Double Win for Vocalink at the 2017 Payments Awards17.11.2017 12:35Tiedote

Vocalink, a Mastercard company, was last night awarded with two prestigious awards - The Overall Winner and the Payments Infrastructure of the Year Award, for its leading technology and expertise, and in recognition for a milestone year that saw Vocalink’s solutions transform the way people and businesses move money across the globe. 2017 saw Vocalink deliver ground-breaking immediate payments solutions both in the US and Thailand as well as enabling access to the UK payments industry through their payments gateway solution PayPort. The business also saw the launch of the new image based cheque clearing system, creating a robust and more efficient system in the UK. RTP ® in the US: This week, Vocalink announced the launch of RTP® (Real-Time Payments) in the US on behalf of The Clearing House; one of the most comprehensive real-tim

Envion AG: Start-up from the Heart of Berlin Has Pioneered Decentralized Mobile Mining by Combining Blockchain with Regenerative Energy17.11.2017 12:00Tiedote

Envion AG has created a technology for the first truly mobile data-center that uses low-priced local energy to mine a broad spectrum of cryptocurrencies (Bitcoin, Ethereum, etc.). By harvesting locally available clean energy right at the source, envion can operate at lower costs than competitors and at the same time reduces the CO2 footprint of the blockchain industry. Envion aims at decentralizing the highly-concentrated mining market (China holds 80% in Bitcoin mining) and at bringing control of the market back to the users. That’s why envion gives 100% of its mining profits back to its community. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171117005011/en/ Envion - World's Most Profitable Standard of Self-Expanding Crypto Infrastructure (Photo: Business Wire) Current challenges in the energy

Chugai's HEMLIBRA® Receives the World's First Regulatory Approval from FDA for Hemophilia A with Inhibitors17.11.2017 02:30Tiedote

Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the U.S. Food and Drug Administration (FDA) has approved the bispecific antibody emicizumab (US product name: HEMLIBRA®) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors. This represents the first regulatory approval for HEMLIBRA® around the world. The US Biologics License Application (BLA) was submitted by Genentech, a member of Roche Group. “We are pleased that HEMLIBRA, a biopharmaceutical created by Chugai scientists based on their exceptional idea, has received its first regulatory approval,” said Chugai’s President & COO, Tatsuro Kosaka. “HEMLIBRA is a first in class biopharmaceutical which is an advancement on the current limited treatment options available for pat

Pacific Drilling Receives Approval of First Day Motions17.11.2017 01:08Tiedote

Pacific Drilling S.A. (OTCPink: PACDQ) (“Pacific Drilling” or the “Company”) today announced that the United States Bankruptcy Court for the Southern District of New York has granted the relief requested by the Company in certain first day motions related to ordinary course business activities, subject to certain modifications at the request of the Court, the United States Trustee and stakeholders. The approved motions give us the authority to, among other things, continue to pay employee wages and benefits without interruption, to utilize our current cash management system, and to pay certain foreign and critical vendors for goods and services provided prior to the petition date. All vendors will be paid in full and in cash on normal payment terms for all goods and services provided on or after the petition date. Paul Reese, Chief Executive Officer of Pacific Drilling, said, “With the

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme